CN114632093A - Nano substance for treating eczema - Google Patents

Abstract

The invention relates to the field of medicines, in particular to application of a yolk distillation oil nano substance (carbon dots/nano particles/nano components). The carbon point of the yolk distillation oil is obtained from the yolk distillation oil by technical methods such as separation and purification, and pharmacological experiments show that: the carbon point of the yolk oil has definite therapeutic effect on chronic eczema.

Description

Nano substance for treating eczema

Technical Field

The invention relates to the field of medicines, in particular to application of nano substances (carbon dots/nano particles/nano components) in yolk distillate oil, and more particularly relates to application of yolk distillate oil nano particles, yolk distillate oil nano components and yolk distillate oil carbon dots.

Background

The invention relates to application of nanoparticles (nanoparticles/carbon quantum dots/carbon dots) extracted, separated and purified from yolk distillate oil in the field of medicines, and the nanoparticles/carbon quantum dots/carbon dots are mainly used for relieving eczema symptoms and have anti-inflammatory activity.

Yolk oil is derived from the prescription for treating the fire burn and sore of soup from Ji Yan Fang of monk Yao Yueyuan in North Wen, one ten cooked chickens are taken, oil is taken from yellow frying, greasy powder is added, the mixture is stirred evenly, and the yellow feathers are used for sweeping the sore to permanently remove the scar. Egg yolk oil is yolk extract of fresh egg of domestic chicken of Phasianidae, has sweet taste and neutral nature, and has effects of relieving swelling, removing toxic substance, healing sore and promoting granulation. Mainly contains various components such as lecithin, protein, riboflavin, oleic acid, linoleic acid, fatty acid, vitamin, zinc selenium and the like.

The method for clinical application comprises parching ovum gallus Domesticus flavus, removing ovum gallus Domesticus album from cooked ovum gallus Domesticus, mashing ovum gallus Domesticus flavus, placing in small iron ladle or copper ladle, heating and decocting over fire until the ovum gallus Domesticus flavus turns from yellow to black and makes a squeak sound, and overflowing oil to obtain brown or black viscous liquid as ovum gallus Domesticus flavus distillate oil. The medicine needs to be burnt at present, is inconvenient to use, easily pollutes clothes, has large smell and is difficult to accept, and the safety of the medicine is not guaranteed.

Disclosure of Invention

The invention extracts the separated carbon dots (nano particles/nano particles) from the yolk distillate oil, and finds that the carbon dots have remarkable biological effect of treating eczema. Has the value of further development and utilization.

Use of egg yolk oil and nanoparticles thereof in compositions for treating dermatological disorders. The skin diseases can be any one of contact dermatitis, eczema, urticaria, allergic cutaneous vasculitis and drug dermatitis.

The skin disease is eczema.

The composition may or may not contain pharmaceutically acceptable excipients.

The yolk distillation oil nano-particles are selected from any one of yolk distillation oil nano-particles, yolk distillation oil carbon quantum dots and yolk distillation oil carbon dots.

Drawings

FIG. 1 is a topographical map of egg yolk oil carbon dots (EYO-CDs)

FIG. 1A is a low resolution electron microscopy topographic phase diagram of EYO-CDs

FIG. 1B is a bar graph of the particle size distribution of EYO-CDs

FIG. 1C is a high resolution electron microscopy topographic phase diagram of EYO-CDs

FIG. 1D is a UV spectrum of EYO-CDs

FIG. 1E is a diagram of the fluorescence spectrum of EYO-CDs

FIG. 1F is an infrared spectrum of EYO-CDs

FIG. 2 is a graph of staining of carbon spots (EYO-CDs) of yellow distilled oil on HE (human epidermal growth factor) of ear skin tissue of chronic eczema mice

FIG. 2A is a graph showing HE staining of ear skin tissue of mice in blank group

FIG. 2B model group mouse ear skin tissue HE staining pattern

FIG. 2C HE staining pattern of ear skin tissue of mice in positive drug group

FIG. 2D HE staining pattern of ear skin tissue of EYO-CDs low-dose mice

FIG. 2F HE staining pattern of ear skin tissue of mice at medium dose in EYO-CDs

FIG. 2E HE staining pattern of ear skin tissue of EYO-CDs high dose mice

Detailed Description

The technical solutions of the present invention will be clearly and completely described below with reference to specific embodiments, however, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments obtained by a person skilled in the art without making any inventive step are within the scope of protection of the present invention.

Example 1: preparation of yolk distillation oil carbon dots

The purchased egg yolk powder of the same batch is weighed and then put into a crucible. Covering the opening of the crucible with aluminum foil paper, covering the cover tightly, and putting the crucible in a muffle furnace for carbonization.

The muffle furnace heating process comprises the following steps: heating to 260 ℃, wherein the heating process lasts for 1h, and the heating process lasts for 1 h; and opening the furnace door after the temperature is reduced to the room temperature, and taking out the crucible, wherein the product in the crucible is the yolk distilled oil.

The carbon point purification steps of the egg yolk distillation oil are as follows: the yolk oil was extracted three times with deionized water, filtered through a 0.22 μm microfiltration membrane and concentrated. Then using deionized water as dialysis medium, dialyzing the concentrated solution with 1000D dialysis membrane for 7 days, and taking out the solution in the bag, namely the carbon point of the egg yolk distillation oil.

Example 2 investigation of Fuchu oil charcoal Point eczema-alleviating Effect

SPF grade ICR mice 42, randomly divided into 6 groups, each group of 7, were blank group, 2, 4-Dinitrochlorobenzene (DNCB) induced chronic eczema model group, compound dexamethasone acetate cream positive drug control group, EYO-CDs low 10.8(g/ml), medium 21.6(g/ml), high 43.2(g/ml) dose group. The abdomen of the mice was dehaired 2X 2cm the day before the experiment. Except for the blank group, mice in each of the other groups were sensitized by applying 100. mu.L of 7% DNCB alcohol solution to the abdominal hair removal area on the 1 st day of the experiment. On day 5, the mice were challenged with 10. mu.L of 1% DNCB alcohol solution evenly in the right ear, lateral ear, and abdominal depilatory, 4 times every other day thereafter. After the initial excitation for 24 hours, the right ear of each group of mice is administrated on the front and back sides, the blank group and the model group are administrated with 10 mu L of physiological saline, the positive medicine group is administrated with 20 mg/ear of compound dexamethasone acetate cream, and the EYO-CDs group is administrated according to low dose, medium dose and high dose, each 10 mu L, and the administration is carried out once every other day for 4 times. Blood was collected from the eyeball 24 hours after the last administration, and then the mice were sacrificed, and both ears were excised and examined for the corresponding indices. And (3) carrying out eye ball picking and blood taking 24 hours after the last administration, then killing the mice, standing the blood for half an hour, centrifuging for 15min at 3000r/min, taking the supernatant, and detecting IL-4 and IFN-gamma in the blood according to the requirements of an ELISA kit. The punch cuts the tissues at the same positions in the middle of the two ears, the weight is weighed, the thickness is measured by a micrometer caliper, and finally the tissues of the right ear are fixed in 10 percent paraformaldehyde, embedded in paraffin, HE stained and observed under 200 light microscope. Cutting all tissues of the left auricle, rinsing with normal saline, wiping, weighing, adding 9 times of normal saline, grinding with a tissue triturator, centrifuging at 3000r/min for 10min, and taking the supernatant. According to the requirements of the kit, IL-4 and IL-17 in the mouse ear tissue homogenate are detected.

EYO-CDs measurement of thickness and weight of the right ear of chronic eczema mice (see Table 1): after 4 times of administration, compared with a model group, the positive medicine group has obvious reduction on the swelling thickness difference and weight difference of the right ear and the left ear of a mouse, compared with the model group, EYO-CDs dosage groups have reduction on the swelling thickness difference and weight difference of the right ear and the left ear of the mouse in different degrees, and a certain dose-effect relationship exists, so that the higher the concentration is, the better the effect of reducing the swelling thickness and the weight of the ears is. Compared with the model group, the difference of each group has statistical significance (P is less than 0.05 or P is less than 0.01).

Table 1 ear thickness ear weight comparison of groups of mice (x ± s, n ═ 7)

Comparison with model groups: p < 0.05, P < 0.01

The detection results of the concentration levels of IL-4 and IFN-gamma in the serum of each group of mice (see Table 2): compared with the model group, the IL-4 content in the serum of mice of each dose group of the positive drug group and EYO-CDs is reduced to different degrees (P is less than 0.01), compared with the model group, the IFN-gamma content in the positive drug group, EYO-CDs and the high dose group is improved to different degrees (P is less than 0.01), and the low dose group has no obvious difference (P is more than 0.05). Compared among treatment groups, the serum IL-4 content of EYO-CDs high, medium and low dose mice is higher than that of the positive drug group, and the IFN-gamma content is lower than that of the positive drug group (P is less than 0.01), but a certain dose-effect relationship exists, and the higher the concentration of EYO-CDs group is, the higher the IL-4 reduction degree and the IFN-gamma increase degree are.

TABLE 2 comparison of IL-4 and IFN-y concentration levels in serum of mice in each group (x + -s, n-7, pg/ml)

The results of the measurement of IL-4 and IL-17 concentrations in the ear tissues of each group of mice (see Table 3): compared with the model group, the IL-4 and IL-17 in each administration group are reduced to different degrees, the IL-4 in the positive medicine group and the IL-17 content are the lowest, and the IL-4 and IL-17 content in the ear tissues of the mice is reduced (P is less than 0.01 or P is less than 0.05) along with the increase of the medicine concentration in each EYO-CDs dosage group.

TABLE 3 comparison of IL-4 and IL-17 concentration levels in the tissues of each group of mice (x. + -.s, n. about.7, pg/ml)

Comparison with model groups: p < 0.05, P < 0.01

EYO-CDs histopathological results on ear skin of chronic eczema mice: FIG. 2 shows that the ear skin tissue structure of the blank group of mice is normal, the epidermis thickness is normal, no edema exists, no obvious lymphocyte infiltration exists, and the blood vessel morphology is normal. The chronic eczema model group mice have the advantages of ear epidermal necrosis, stratum granulosum thickening, acanthosis thickening, intracellular and intercellular edema, a large number of inflammatory cells in dermis, lymphocyte infiltration and obvious dermal blood vessel dilatation and congestion. The positive drug group mice have normal epidermis structures and slight keratinization, the edema of epidermis and dermis is obviously reduced, and inflammatory cells are obviously reduced. EYO-CDs low dose group had slightly reduced epidermal keratinization, edema and inflammatory cell infiltration, EYO-CDs medium dose group had slightly reduced epidermal keratinization, clear structure, significantly reduced inflammatory factors, and slight edema. EYO-CDs high dose group ear tissue epidermis structure is normal, keratinization is reduced obviously, edema, lymphocyte infiltration are reduced greatly, thickening degree is reduced obviously, blood vessel morphology is normal. It shows that EYO-CDs have good effect of treating eczema.

Claims (7)

1. Application of yolk oil nano-material (carbon dots/nano-particles/nano-ingredients).

2. The use according to claim 1 for the treatment of a dermatological disorder, wherein said dermatological disorder is any one of contact dermatitis, eczema, urticaria, allergic cutaneous vasculitis, and drug dermatitis.

3. The use according to claim 1 for the treatment of a dermatological disorder, wherein the dermatological disorder is eczema.

4. The use according to claim 1 for the treatment of dermatological disorders, wherein said composition is with or without pharmaceutically acceptable excipients.

5. The use according to claim 1 for the treatment of a dermatological disorder, wherein the mayonnaise oil nanoparticles are selected from any one of mayonnaise oil nanoparticles, mayonnaise oil carbon quantum dots, and mayonnaise oil carbon dots.

6. The use of claim 1 for the treatment of dermatological disorders, wherein the composition is any one of a pharmaceutical, a nutraceutical, and a food product, and the composition is formulated into a clinically acceptable topical formulation; further preferably, the clinically acceptable ointment, liniment, gel and plaster.

7. The use according to claim 1 for the treatment of dermatological disorders, wherein the composition is a gas oil nanosubstance applied alone or in combination with other drugs.

Images